Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | EPAS1 | Q99814 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MERTK | Q12866 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28738890 | 0.91 | EPAS1 (0.55) | L3MBTL1EPAS1ALDH1A1HTTRAB9A | |
| SCHEMBL4930639 | 0.91 | L3MBTL1 (0.62) | L3MBTL1EPAS1ALDH1A1MAPTPOLB | |
| SCHEMBL2503793 | 0.88 | EPAS1 (0.66) | L3MBTL1EPAS1ALDH1A1MAPTPOLB | |
| SCHEMBL2508268 | 0.87 | ALDH1A1 (0.59) | L3MBTL1EPAS1ALDH1A1HTTRAB9A | |
| SCHEMBL30378593 | 0.87 | ALDH1A1 (0.59) | L3MBTL1EPAS1ALDH1A1HTTRAB9A | |
| SCHEMBL2324309 | 0.85 | L3MBTL1 (0.56) | L3MBTL1ALDH1A1HTTMAPTMAPK1 | |
| SCHEMBL4932746 | 0.85 | MEN1 (0.63) | L3MBTL1EPAS1ALDH1A1RAB9AMAPT | |
| SCHEMBL3253899 | 0.84 | L3MBTL1 (0.77) | L3MBTL1EPAS1ALDH1A1MAPTPOLB | |
| Hydrochloric Acid SCHEMBL11533078 | 0.84 | MAPK1 (0.57) | L3MBTL1EPAS1ALDH1A1MAPTPOLB | |
| SCHEMBL8885999 | 0.82 | MEN1 (0.57) | L3MBTL1EPAS1ALDH1A1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | GRUENENTHAL GMBH (DE) | 2013-09-05 | — | — | US | claimed |
| US-8455475-B2 | Substituted spiro-amide compounds | GRUENENTHAL GMBH (DE) | 2013-06-04 | — | — | US | claimed |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-30 | — | — | US | claimed |
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | GRUENENTHAL GMBH (DE) | 2013-09-05 | — | — | US | disclosed |
| US-8455475-B2 | Substituted spiro-amide compounds | GRUENENTHAL GMBH (DE) | 2013-06-04 | — | — | US | disclosed |
| EP-1474415-B1 | 1-PHENYL-2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES, THE USE THEREOF FOR PRODUCING DRUGS USED IN THE TREATMENT OF IMMUNOLOGICAL DISEASES | BAYER SCHERING PHARMA AG (DE) | 2011-07-27 | — | — | EP | disclosed |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
| US-7683081-B2 | 1-phenyl-2-heteroaryl-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-03-23 | — | — | US | disclosed |
| WO-2008114009-A1 | 10H-BENZO(G)PTERDINE-2,4-DIONE COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CAMBRIDGE ENTERPRISE LTD. (GB) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008114009-A1 | 10H-BENZO(G)PTERDINE-2,4-DIONE COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CAMBRIDGE ENTERPRISE LTD. (GB) | 2008-09-25 | — | — | WO | disclosed |
| CN-1317274-C | 1-phenyl-2-heteroaryl-substituted benzimdazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AG (DE) | 2007-05-23 | — | — | CN | disclosed |
| US-20050267160-A1 | 1-Phenyl-2-heteroaryl-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-12-01 | — | — | US | disclosed |
| US-6962932-B2 | 1-phenyl-2-heteroaryl-substituted benzimdazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-11-08 | — | — | US | disclosed |
| CN-1633429-A | 1-phenyl-2-heteroaryl substituted benzimidazole derivatives, their use for the preparation of medicaments and pharmaceutical compositions containing them | SCHERING AG (DE) | 2005-06-29 | — | — | CN | disclosed |
| EP-1474415-A1 | 1-PHENYL-2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES, THE USE THEREOF FOR PRODUCING DRUGS USED IN THE TREATMENT OF IMMUNOLOGICAL DISEASES | Schering Aktiengesellschaft (DE) | 2004-11-10 | — | — | EP | disclosed |
| US-20030229085-A1 | 1-Phenyl-2-heteroaryl-substituted benzimdazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-12-11 | — | — | US | disclosed |
| WO-2003068766-A1 | 1-PHENYL-2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES, THE USE THEREOF FOR PRODUCING DRUGS USED IN THE TREATMENT OF IMMUNOLOGICAL DISEASES | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | BDKRB1, BDKRB2, REN | L3MBTL1 3172/4885EPAS1 1068/4885ALDH1A1 2086/4885 |
| US-20050267160-A1 | 1-Phenyl-2-heteroaryl-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | CD4, NFATC1, ICOS | L3MBTL1 3290/4885EPAS1 1984/4885ALDH1A1 1382/4885 |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | BDKRB1, BDKRB2, REN | L3MBTL1 3172/4885EPAS1 1068/4885ALDH1A1 2086/4885 |
| US-20030229085-A1 | 1-Phenyl-2-heteroaryl-substituted benzimdazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | CD4, ICOS, NFATC1 | L3MBTL1 2419/4885EPAS1 2574/4885ALDH1A1 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.